A New Class of Anticancer Agents
Chem Biol Drug Des 2014; 83: 126–131 Research Letter Mefloquine–Oxazolidine Derivatives: A New Class of Anticancer Agents Felipe A. R. Rodrigues1, Igor da S. Bomfim1, applications in other fields, such as against Gram-positive Bruno C. Cavalcanti1, Claudia Pessoa1, Raoni and Gram-negative bacteria (1), in particular against Myco- S. B. Goncalves2, James L. Wardell2,3, Solange bacterium tuberculosis (2,3) and Mycobacterium avium M. S. V. Wardell4 and Marcus V. N. de Souza2,* complex (MAC) (4,5) and also against schistosomiasis (6), neurodegenerative, and (neuro-) inflammatory diseases (7). 1Laboratorio de Oncologia Experimental, Universidade A clear indication of the promise of this drug in fields other Federal do Ceara, Fortaleza, CE 3157, Brazil than malaria is the number of recent patent applications 2FioCruz-Fundacßao~ Oswaldo Cruz, Instituto de Tecnologia (5,7,8). More recently, much attention has been paid to the em Farmacos-Far-Manguinhos, Rua Sizenando Nabuco, potential perspectives of MQ as an anticancer agent. As 100, Manguinhos, 21041-250, Rio de Janeiro, RJ 35513, estimated by the National Institutes of Health (NIH), the over- Brazil all costs of cancer in 2007 were $226.8 billion.a Cancer is a 3Department of Chemistry, University of Aberdeen, Old leading cause of deaths worldwide and accounted for 7.6 Aberdeem, Aberdeem, AB 24 3UE, UK b 4CHEMSOL, 1 Harcourt Road, Aberdeen, AB15 5NY, UK million deaths (13% of all deaths) in 2008. Louie and *Corresponding author: Marcus V. N. de Souza, coworkers (9) found MQ to be the most potent anticancer marcos_souza@far.fiocruz.br drug when compared to chloroquine and the fluoroquino- lone drugs cipro and levofloxacin.
[Show full text]